ISR in Fibrosis: eIF2α-ATF4 Pathway to ISRIB Drug Discovery
Four kinases (PERK/PKR/GCN2/HRI) converge on eIF2α-ATF4. ISR role in IPF, MASH, and neurodegeneration, plus the ISRIB-led drug development landscape.
1. What ISR Is: The Central Hub of Cellular Stress
The Integrated Stress Response (ISR) is a highly conserved system that funnels diverse stresses — ER stress, amino acid deprivation, viral infection, heme depletion — into a single convergent signal: eIF2α phosphorylation.
ISR originally evolved for short-term survival and adaptation, but chronic activation drives cell death, fibrosis, and neurodegeneration. In recent years, ISRIB (ISR inhibitor) and related compounds have advanced into clinical trials for IPF, cognitive disorders, and ALS.
This article outlines ISR's molecular machinery, crosstalk with TGF-β/Smad and UPR, organ-level evidence, and the current drug development landscape.
2. Molecular Machinery of ISR
Four eIF2α Kinases
ISR is initiated by four stress-specific kinases.
- PERK (EIF2AK3): ER stress (one arm of the UPR)
- PKR (EIF2AK2): double-stranded RNA (viral infection)
- GCN2 (EIF2AK4): amino acid deprivation, UV exposure
- HRI (EIF2AK1): heme depletion, oxidative stress, mitochondrial stress
The eIF2α-ATF4 Axis
- Each kinase phosphorylates eIF2α at Ser51
- eIF2B (the GEF) is inhibited → global translation is suppressed
- However, uORF-containing mRNAs (such as ATF4) are selectively translated
- ATF4 drives target genes (CHOP, GADD34, ATF3, ASNS)
Feedback Loops
- GADD34 (PPP1R15A): pairs with PP1 to dephosphorylate eIF2α → translation restored
- CHOP (DDIT3): drives apoptosis under chronic stress
- Guanabenz / Sephin1: GADD34 inhibitors that prolong ISR — neuroprotective candidates
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
3. Crosstalk with Major Pathways
ISR × UPR
- The PERK arm of UPR is the core of ISR
- IRE1α and ATF6 arms act independently but cooperatively
ISR × TGF-β
- ATF4 targets overlap with TGF-β/Smad targets (COL1A1, CTGF)
- TGF-β itself activates PERK, forming a pro-fibrotic loop
ISR × Autophagy
- ATF4 induces ATG5, ATG7, LC3B
- Short-term: survival strategy. Chronic: selective autophagy (mitophagy, ER-phagy) breakdown
4. Organ-Level Evidence
Lung: IPF and Epithelial Stress
- SFTPC-mutant familial IPF: chronic ER stress → PERK-eIF2α-ATF4 constitutively active
- Type II alveolar cell ISR chronicity triggers fibrotic foci formation
- Calico/AbbVie's ABBV-CLS-7262 (ISRIB derivative) has cleared Phase 1 in IPF
Liver: MASH/NASH
- Hepatocyte lipid accumulation → ER stress → PERK activation → ATF4-CHOP-mediated cell death
- In hepatic stellate cells, by contrast, ISR promotes myofibroblast differentiation
- This cell-type-dependent duality is the drug-discovery challenge
Nervous System: Neurodegeneration Meets Fibrosis
- Chronic ISR activation in ALS, FTD, and prion disease
- ISRIB improves cognitive function in animal models; Calico is advancing clinical development
- Glial scarring in multiple sclerosis (the CNS analog of fibrosis) also involves ISR
Heart: Pressure-Overload Failure
- TAC models show sustained PERK-eIF2α-ATF4 activation in cardiomyocytes
- Chronicity promotes cardiac fibrosis and diastolic dysfunction
5. Drug Development: The Rise of ISR Modulators
ISRIB (Integrated Stress Response Inhibitor)
- Mechanism: restores eIF2B activity → selectively blocks downstream ISR (ATF4 translation)
- Discovery: Peter Walter lab (UCSF), 2013 eLife
- Design advantage: does NOT block eIF2α phosphorylation itself — upstream signaling remains intact
- Clinical development: licensed to Calico, co-developed with AbbVie
ABBV-CLS-7262
- Oral ISRIB derivative from Calico × AbbVie
- Indications: ALS (Phase 2 complete), Vanishing White Matter disease
- Fibrosis indications: IPF and progressive pulmonary fibrosis under evaluation
GADD34 Inhibitors (Reverse Approach)
- Guanabenz (former antihypertensive), Sephin1 (Guanabenz derivative)
- Prolong ISR to achieve neuroprotection
- Clinical trials in Charcot-Marie-Tooth disease and ALS
PERK-Selective Inhibitors
- GSK2606414, GSK2656157: preclinical efficacy but pancreatic β-cell toxicity slowed development
- Next-generation PERK inhibitors are under active design
6. Use in Preclinical Research
Measuring ISR Activation
- p-eIF2α (Ser51) Western blot: the most direct readout
- ATF4 nuclear staining: IHC/IF
- ISR target gene panel: Atf4, Ddit3 (Chop), Ppp1r15a (Gadd34), Asns, Trib3 by RT-qPCR
- Polysome profiling: simultaneous view of global translation suppression + selective translation
Disease Models
- Tunicamycin / thapsigargin: ER stress induction
- Amino-acid-restricted media: GCN2-specific activation
- Poly(I:C) treatment: PKR activation
- Pulmonary fibrosis models (BLM): useful for observing chronic ISR
Genetic Tools
- Eif2ak3^flox (PERK conditional)
- Atf4^-/- (embryonic lethality is high — tissue-specific KO preferred)
- Ddit3 (Chop)^-/-: shows protection in fibrosis models
7. FAQ
Q1: What's the difference between ISR and UPR?
UPR is an ER-stress-specific three-arm response (PERK, IRE1α, ATF6), while ISR refers to the eIF2α-ATF4 convergence point that integrates diverse stresses. PERK is part of ISR; IRE1α and ATF6 are not — this is the key organizing principle.
Q2: Does ISRIB suppress fibrosis?
IPF models show anti-fibrotic effects, but ISRIB also blocks physiologic ISR (cellular adaptation), so systemic dosing requires careful side-effect management. ABBV-CLS-7262's design addresses this balance.
Q3: Can we target ATF4 directly?
Transcription factors are hard to drug directly. Practical targets are upstream eIF2B (ISRIB), PERK (selective inhibitors), or downstream CHOP/GADD34.
Q4: Are ISR-targeting drugs promising in MASH?
Hepatocyte ISR is anti-fibrotic while hepatic stellate cell ISR is pro-fibrotic — this duality demands careful design for systemic ISRIB. Stellate-cell-selective delivery (LNP, etc.) is the next-generation approach.
Q5: What's the minimum assay set for evaluating ISR?
- p-eIF2α/total eIF2α Western, 2) ATF4 nuclear IHC, 3) Atf4/Ddit3/Ppp1r15a RT-qPCR — the standard triad. Time-course data distinguishes acute vs chronic activation, which often matters more than the absolute signal.
Related Articles
- TGF-β/Smad Pathway — Fibrotic pathway that reinforces ISR
- Unfolded Protein Response (UPR) — Upstream of ISR's PERK arm
- HIF Pathway and Fibrosis — Intersection with hypoxic stress
- Notch Signaling Pathway — Stress response and cell fate
- Fibrosis Mechanisms: Myofibroblasts as Drug Targets — Integrated mechanistic view
- BLM Pulmonary Fibrosis Model — Useful for observing chronic ISR
- IPF Treatment Landscape 2025 — Where ABBV-CLS-7262 fits
References
- Costa-Mattioli M, Walter P. The integrated stress response: From mechanism to disease. Science. 2020;368(6489):eaat5314. PMID: 32327570
- Sidrauski C, et al. Pharmacological brake-release of mRNA translation enhances cognitive memory. eLife. 2013;2:e00498. PMID: 23741617
- Pakos-Zebrucka K, et al. The integrated stress response. EMBO Rep. 2016;17(10):1374-1395. PMID: 27629041
- Harding HP, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000;6(5):1099-1108. PMID: 11106749
- Wang L, et al. Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors. Nat Chem Biol. 2012;8(12):982-989. PMID: 23086298
- Tsai JC, et al. Structure of the nucleotide exchange factor eIF2B reveals mechanism of memory-enhancing molecule. Science. 2018;359(6383):eaaq0939. PMID: 29599213
- Das I, et al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science. 2015;348(6231):239-242. PMID: 25859045
- Lawson CA, et al. Targeting translation in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2022;66(3):262-270. PMID: 34705620